Holger Lembrér will leave his role as Chief Financial Officer at Oncopeptides
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announced that Holger Lembrér, Chief Financial Officer (CFO) has decided to leave Oncopeptides to pursue a new role in another company. Holger was appointed CFO in January 2023. He will continue in his current role until December or until a new CFO takes office. A recruitment process will be initiated immediately.
“Holger has played an important role in the transition of Oncopeptides to a commercial company. I am grateful for his contribution and wish him the best in his future endeavors", says Monica Shaw, CEO at Oncopeptides.